循環器内科

論文業績

2.　Kokura Y, Kishimori T, Kato T, Iwasaki Y, Wada A, Tani A, Yamaji R, Koike J, Matsumoto T, Yagi T, Sekine O, Okada M. Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes. Diabetes Res Clin Pract. 2026 Aug;238:113404. doi: 10.1016/j.diabres.2026.113404. Epub 2026 Jul 1. PMID: 42385946.

1.　Kishimori T, Kato T, Iwasaki Y, Shimada T, Wada A, Tani A, Yamaji R, Koike J, Matsumoto T, Yagi T, Okada M. Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes. Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70433. Epub ahead of print. PMID: 41492180.

8.　Iwasaki Y, Shimada T, Kishimori T, Kato T, Koike J, Matsumoto T, Yagi T, Okada M. Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. Diabetes Res Clin Pract. 2025 Dec 23;231:113072. doi: 10.1016/j.diabres.2025.113072. Epub ahead of print. PMID: 41448390.

7.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2025 Nov 4;13(6):e005364. doi: 10.1136/bmjdrc-2025-005364. PMID: 41192940; PMCID: PMC12588009.

6.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes. J Card Fail. 2025 Sep 12:S1071-9164(25)00376-8. doi: 10.1016/j.cardfail.2025.07.026. Epub ahead of print. PMID: 40945773.

5.　Iwasaki Y, Shimada T, Kishimori T, Wada A, Koike J, Matsumoto T, Yagi T, Okada M. Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease. JACC Adv. 2025 Sep;4(9):102074. doi: 10.1016/j.jacadv.2025.102074. Epub 2025 Aug 18. PMID: 40829370; PMCID: PMC12391692.

4.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors. Eur Heart J Qual Care Clin Outcomes. 2025 Dec 19;11(8):1319-1328. doi: 10.1093/ehjqcco/qcaf065. PMID: 40676725.

3.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease. Open Heart. 2025 Jul 8;12(2):e003382. doi: 10.1136/openhrt-2025-003382. PMID: 40628673; PMCID: PMC12243591.

2.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes. Sci Rep. 2025 Jul 1;15(1):21333. doi: 10.1038/s41598-025-06245-w. PMID: 40594279; PMCID: PMC12217050.

1.　Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M. Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes. J Am Heart Assoc. 2025 Feb 18;14(4):e037510. doi: 10.1161/JAHA.124.037510. Epub 2025 Feb 8. PMID: 39921523; PMCID: PMC12074738.